During the past decade, Nathan Kline Institute conducted 19 clinical trials. In the 10-year time frame, 19 clinical trials started and 21 clinical trials were completed, i.e. on average, 110.5% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 12 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Nathan Kline Institute" #1 sponsor was "Nathan Kline Institute for Psychiatric Research" with 16 trials, followed by "Hoffmann-La Roche" with 7 trials sponsored, "NYU Langone Health" with 4 trials sponsored, "JANSSEN Alzheimer Immunotherapy Research & Development, LLC" with 3 trials sponsored and "University of California, Los Angeles" with 3 trials sponsored. Other sponsors include 17 different institutions and companies that sponsored additional 21 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Nathan Kline Institute" #1 collaborator was "Nathan Kline Institute for Psychiatric Research" with 6 trials as a collaborator, "National Institute of Mental Health (NIMH)" with 6 trials as a collaborator, "Columbia University" with 4 trials as a collaborator, "National Institute on Aging (NIA)" with 4 trials as a collaborator and "Pfizer" with 4 trials as a collaborator. Other collaborators include 36 different institutions and companies that were collaborators in the rest 27 trials.

According to Clinical.Site data, the most researched conditions in "Nathan Kline Institute" are "Schizophrenia" (20 trials), "Alzheimer's Disease" (7 trials), "Alzheimer Disease" (6 trials), "Autism Spectrum Disorder" (6 trials) and "Schizoaffective Disorder" (6 trials). Many other conditions were trialed in "Nathan Kline Institute" in a lesser frequency.

Most popular intervention types in "Nathan Kline Institute" are "Drug" (45 trials), "Other" (7 trials), "Device" (6 trials), "Behavioral" (3 trials) and "Dietary Supplement" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (22 trials), "D-serine" (5 trials), "placebo" (5 trials), "AVP-786" (2 trials) and "Bapineuzumab 0.5 mg/kg" (2 trials). Other intervention names were less common.

The vast majority of trials in "Nathan Kline Institute" are 54 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Nathan Kline Institute". undefined are not yet recruiting, 7 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 40 completed trials in Nathan Kline Institute, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Nathan Kline Institute, 2 "Phase 1" clinical trials were conducted, 23 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 9 trials that are defined as “Not Applicable".